Literature DB >> 1713717

The pathogenesis of demyelinating disease: insights from cell biology.

A Compston1, N Scolding, D Wren, M Noble.   

Abstract

Cellular and humoral immune mechanisms have been implicated in the pathogenesis of human and experimental demyelinating diseases of the CNS. How these interact in the complex sequence of events that culminates in phagocytosis of myelin by macrophages has yet to be resolved. The relationship between leakage of the blood-brain barrier and demyelination, the reason why recurrent inflammatory demyelination occurs--seemingly in the absence of an antigen-specific immune response--and the lack of effective remyelination all require explanation if a coherent account of immunologically mediated demyelination is to be achieved. One approach to these problems is to study in vitro the developmental and cellular biology of oligodendrocytes--the glial cells responsible for the synthesis and maintenance of CNS myelin. This provides experimental opportunities not offered by more direct investigation of the intact nervous system, but carries the clear disadvantage that observations made in vitro cannot necessarily be extrapolated to humans.

Entities:  

Mesh:

Year:  1991        PMID: 1713717     DOI: 10.1016/0166-2236(91)90099-g

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  11 in total

1.  Limiting and repairing the damage in multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

2.  Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiologic marker.

Authors:  Anat Achiron; Meir Faibel
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 3.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

4.  In the presence of dexamethasone, gamma interferon induces rat oligodendrocytes to express major histocompatibility complex class II molecules.

Authors:  K Bergsteindottir; A Brennan; K R Jessen; R Mirsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

5.  Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients.

Authors:  B Fischer; H Schmoll; P Riederer; J Bauer; D Platt; A Popa-Wagner
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

6.  Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.

Authors:  M G Wing; J Zajicek; D J Seilly; D A Compston; P J Lachmann
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

7.  The expression of CD59 in normal human nervous tissue.

Authors:  C Vedeler; E Ulvestad; L Bjørge; G Conti; K Williams; S Mørk; R Matre
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

8.  Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis.

Authors:  T Vartanian; Y Li; M Zhao; K Stefansson
Journal:  Mol Med       Date:  1995-11       Impact factor: 6.354

9.  Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders.

Authors:  J Roddy; I Clark; B L Hazleman; D A Compston; N J Scolding
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

10.  Immunological mechanisms of demyelination.

Authors:  R A Hughes
Journal:  J R Soc Med       Date:  1992-01       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.